

Patient card

– safety information

CIBINQO®
(abrocitinib)



Side effects can be reported to the Norwegian Medicines Agency
by using this electronic reporting form:

www.legemiddelverket.no/pasientmelding

Safety Information for Patients about Cibinqo:

- This card contains important safety information you should be aware of – before and during treatment with Cibinqo.
- For more information read the patient information leaflet included in each pack of Cibinqo, or at www.felleskatalogen.no.
- Ask your doctor or pharmacist if any of the information is not clear.

Keep this card with you and show to any healthcare professional involved in your medical care – for example, your pharmacist, or an emergency doctor.

You should know about certain side effects and topics listed below, talk to your doctor if you get any side effects.

Sikkerhetsinformasjon



Etter krav fra
Statens legemiddelverk

What Cibinqo is and what it is used for:

Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase inhibitors, which help to reduce inflammation. It works by reducing the activity of an enzyme in the body called 'Janus kinase', which is involved in inflammation.

Cibinqo is used to treat adults with moderate-to-severe atopic dermatitis, also known as atopic eczema. By reducing the activity of Janus kinase enzymes, Cibinqo lessens itching and inflammation of the skin. This in turn can reduce sleep disturbances and other consequences of atopic eczema such as anxiety or depression and improves overall quality of life.

Risk of infections:

Talk to your doctor or pharmacist before and during the treatment with Cibinco if you:

- get symptoms such as fever, wounds, feeling more tired than usual or dental problems as these can be signs of infection.

Vaccines:

Talk to your doctor or pharmacist if you have recently had or plan to have a vaccination (immunisation) - this is because certain live vaccines (e.g. MMR vaccine, yellow fever vaccine, BCG vaccine) are not recommended immediately before and while using Cibinco.

Blood clots in veins or lungs

Talk to your doctor or pharmacist if you:

- get sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm as these can be signs of blood clots in the veins.

Risk of heart disease

Talk to your doctor or pharmacist before and during the treatment if you:

- develop severe chest pain or tightness (that may spread to arms, jaw, neck and back), shortness of breath, cold sweat, light headedness or sudden dizziness, as these may be signs of a heart attack.

Risk of cancer:

Non-melanoma skin cancer has been observed in patients taking Cibirgo. Your doctor may recommend that you have regular skin examinations while taking Cibirgo. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.

Laboratory tests

Your doctor will ask you to get laboratory tests (including testing for high cholesterol) before starting Cibirgo and while you are taking Cibirgo and may adjust your treatment accordingly.

Contraception and pregnancy

Cibirgo must NOT be used during pregnancy.

If you are a woman of childbearing potential, you should use an effective method of contraception during treatment with Cibirgo and for at least one month after your last dose of Cibirgo. Talk to your doctor about suitable methods of contraception.

Tell your doctor straight away if you become pregnant or think you might have become pregnant during treatment.

Other information (please fill in):

Your name:

Doctor's name (who prescribed Cibirgo):

Doctor's phone number:

The date you started Cibirgo: